Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer therapy ‘assists COPD sufferers in smoking cessation’

Pfizer therapy ‘assists COPD sufferers in smoking cessation’

6th November 2009

Pfizer treatment CHANTIX/CHAMPIX (varenicline) was found to help 42.3 per cent of smokers with chronic obstructive pulmonary disease (COPD) cease their habits, it has been reported.

The results of a study into the drug discovered that this percentage of patients also managed to remain abstinent during the final four weeks of treatment, compared to 8.8 per cent of those who were administered a placebo.

According to the firm, up to half of all smokers are at risk of developing COPD ? a condition that includes both chronic bronchitis and emphysema.

Dr Donald Tashkin, study investigator and emeritus professor of medicine at University of California, stated: “This study shows that varenicline is an effective means of smoking cessation for a highly nicotine-dependent, difficult-to-treat group of patients.”

Earlier this week, Pfizer announced that it has formed a brand new firm alongside GlaxoSmithKline, entitled ViiV.

The organisation specialises in developing new treatments and methods of care for those with HIV and AIDS.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.